Article Text

Download PDFPDF

#415 Angiogenetic factors predict clinical outcome in endometrial cancer
  1. Barin Feroz and
  2. Teresa Lucia Pan
  1. Medical University of Innsbruck, Innsbruck, Austria


Introduction/Background Endometrial cancer (EC) is the most common gynecologic tumor in developed countries with poor prognosis in recurrent or metastatic setting. Recent clinical trials have shown activity of anti-angiogenic strategies (i.e. tyrosine kinase inhibitors) in advanced EC.

Methodology Compared to 25 non-malignant control tissues we evaluated RNA expression of ANGPT2, FGF2, VEGFA, PDGFB, PDGFRA, PDGFRB, PDGFA, KIT, VEGFR2 and CXCL8 in 239 EC. We performed association and survival analyses. A subgroup analysis with 81 patients was performed according to the PROMISE molecular classification (POLE, MMRd, p53abn and NSMP).

Results A 2-fold higher expression of PDGFA and VEGFA was found in EC (p<0.001). High expression of PDGFB, on the other hand, was associated with reduced recurrence free survival (RFS; HR 1.932, p=0.018), disease specific survival (DSS HR 2.075, p=0.016) and overall survival (OS; HR 1.616, p=0.021). Similarly, PDGFRA was associated with DSS (HR 2.200, p=0.048), ANGPT2 with RFS and DSS (HR 1.908, p=0.011 and HR 2.293, p=0.004, respectively) and VEGFA with RFS (HR 1.717, p=0.039). Additionally, PDGFRA (DSS HR 3.164) and PDGFB (OS HR 1.565) proved to be predictive markers in Cox regression analyses. The expression of PDGFRA and PDGFRB was significantly different between the PROMISE molecular subtypes.

Conclusion Various angiogenetic molecules influence the clinical prognosis and their predictive value should be evaluated for anti-angiogenetic therapy.

Disclosures No disclosures

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.